Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Given Average Rating of “Hold” by Analysts
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has been given an average rating of “Hold” by the twelve research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $8.42.
Several equities research analysts have recently weighed in on the stock. Maxim Group increased their price objective on shares of Keryx Biopharmaceuticals from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Monday, May 15th. ValuEngine cut shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, June 2nd. Finally, Cowen and Company reiterated a “hold” rating on shares of Keryx Biopharmaceuticals in a research report on Saturday, June 17th.
A number of large investors have recently bought and sold shares of the company. Metropolitan Life Insurance Co. NY boosted its stake in Keryx Biopharmaceuticals by 6.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 64,077 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 3,994 shares during the last quarter. Norges Bank bought a new stake in Keryx Biopharmaceuticals during the fourth quarter worth approximately $9,973,000. Lincoln Capital Corp bought a new stake in Keryx Biopharmaceuticals during the fourth quarter worth approximately $158,000. Teachers Advisors LLC boosted its stake in Keryx Biopharmaceuticals by 3.3% in the fourth quarter. Teachers Advisors LLC now owns 138,874 shares of the biopharmaceutical company’s stock worth $814,000 after buying an additional 4,402 shares during the last quarter. Finally, Bank of Montreal Can bought a new stake in Keryx Biopharmaceuticals during the first quarter worth approximately $434,000. Institutional investors and hedge funds own 62.26% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Given Average Rating of “Hold” by Analysts” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/07/11/keryx-biopharmaceuticals-inc-nasdaqkerx-given-average-rating-of-hold-by-analysts.html.
Shares of Keryx Biopharmaceuticals (NASDAQ KERX) traded up 3.48% during trading on Tuesday, hitting $8.03. 798,519 shares of the stock traded hands. The firm has a 50-day moving average of $6.45 and a 200-day moving average of $5.85. The firm’s market capitalization is $870.98 million. Keryx Biopharmaceuticals has a 1-year low of $4.03 and a 1-year high of $8.21.
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by $0.03. Keryx Biopharmaceuticals had a negative return on equity of 1,122.28% and a negative net margin of 387.12%. The firm had revenue of $11.82 million for the quarter, compared to analyst estimates of $10.19 million. During the same quarter last year, the company earned ($0.39) earnings per share. The company’s quarterly revenue was up 73.2% compared to the same quarter last year. On average, equities analysts forecast that Keryx Biopharmaceuticals will post ($0.69) earnings per share for the current year.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.